Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature
European Journal of Clinical Microbiology & Infectious Diseases · 2024
DOI: 10.1007/s10096-024-04849-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Barthelemy Lafon-Desmurs und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Gustave Dron, Department of Infectious Diseases, Service Universitaire Des Maladies Infectieuses, 59210, Tourcoing, France. blafon…. Hauptthemen laut MEDLINE: Teicoplanin, Drug Monitoring, Anti-Bacterial Agents, Prosthesis-Related Infections. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2-7). Median time between two reinjections was 57 days (IQR 28-82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9% of dosages (93/95) and above 8 mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Gustave Dron, Department of Infectious Diseases, Service Universitaire Des Maladies Infectieuses, 59210, Tourcoing, France. blafondesmurs@ch-tourcoing.fr.
- Centre Hospitalier Gustave Dron, Department of Infectious Diseases, Service Universitaire Des Maladies Infectieuses, 59210, Tourcoing, France.
- METRICS ULR 2694, Biostatistics, Lille, France.
- Lille University Hospital, Department of Pharmacology and Toxicology, Lille, France.
- Lille University Hospital, Department of Pharmacology, Lille, France.
- Centre Hospitalier Gustave Dron, Department of Microbiology, Tourcoing, France.
Zitieren
APA
Lafon-Desmurs, B., Gachet, B., Hennart, B., Valentin, B., Roosen, G., Degrendel, M., Loiez, C., Beltrand, E., D'Elia, P., Migaud, H., Robineau, O., & Senneville, E. (2024). Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04849-0
Vancouver
Lafon-Desmurs B, Gachet B, Hennart B, Valentin B, Roosen G, Degrendel M, et al. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04849-0
BibTeX
@article{LafonDesmurs2024,
author = {Lafon-Desmurs, Barthelemy and Gachet, Benoit and Hennart, Benjamin and Valentin, Benjamin and Roosen, Gabrielle and Degrendel, Maxime and Loiez, Caroline and Beltrand, Eric and D'Elia, Piervito and Migaud, Henri and Robineau, Olivier and Senneville, Eric},
title = {Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
doi = {10.1007/s10096-024-04849-0}
}
EUVIMED